Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas

Background. Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results. Patients and Methods. Analysis of consecutive patients with neuroendocrine carc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Olsen, Ingrid H., Sørensen, Jens B., Federspiel, Birgitte, Kjaer, Andreas, Hansen, Carsten P., Knigge, Ulrich, Langer, Seppo W.
Formato: Artigo
Idioma:Inglês
Publicado: The Scientific World Journal 2012
Assuntos:
Clinical Study
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3432352/
https://ncbi.nlm.nih.gov/pubmed/22973169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1100/2012/170496
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares